Dupilumab for atopic dermatitis has only just made it onto the PBS but already a competing product is making its mark in clinical trials. The JAK1 inhibitor abrocitinib has stacked up well against dupilumab and better than placebo in a phase 3 RCT of adults with moderate to severe atopic dermatitis unresponsive to topical therapies. ...
New biologic trialled against dupilumab for atopic dermatitis
By Mardi Chapman
25 Mar 2021